ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Gilead Sciences, Inc." (GILD) Report Updated: Dec 15, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Gilead Sciences, Inc." (GILD)

Rating: Strong Buy Volatility: Conservative
Total Grade: A Industry: Biotechnology
Competitors: REGN, ANAC, FOLD, CBPO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: A down no change
Last Week: A same upgrade
Two Weeks Ago: B up no change
service keys

"Gilead Sciences, Inc."© quotemedia

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; Viread and Hepsera oral formulations for the treatment of chronic hepatitis B; Letairis, an oral formulation for pulmonary arterial hypertension; Ranexa, a tablet for chronic angina; Lexiscan/Rapiscan, a test that detects and characterizes coronary artery disease; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, a capsule for the treatment and prevention of influenza A and B. The company also provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. In addition, it has product candidates in various stages for the treatment of HIV, which include integrase single-tablet regimen Quad; Cobicistat and Elvitegravir in Phase III; and GS-7340 in Phase II, as well as for liver disease, which consist of GS-7977 in Phase III; GS-5885, GS-9451, and GS-6624 in Phase II; and GS-7340, GS-9620, and GS-9669 in Phase I. Further, the company’s product candidates in various stages for the treatment of cardiovascular/metabolic diseases comprise Ranolazine in Phase III; and for the treatment of respiratory diseases consist of Aztreonam for inhalation solution in Phase III, as well as GS-6624 in Phase I. Additionally, it has product candidates in various stages for inflammation/oncology diseases that include GS-1101 in Phase III; GS-1101 and GS-6624 in Phase II; and GS-9973 in Phase I. The company was founded in 1987 and is headquartered in Foster City, California.

Recent News: "Gilead Sciences, Inc."